← Oncology Approval Tracker

FDA DECISION ·

Decnupaz

pivekimab sunirine-pvzy · AbbVie

FDA approvalNew therapyBPDCN
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

LAMPGEN ANALYSIS

Why it matters

A CD123-directed antibody-drug conjugate adds a treatment option for an ultra-rare blood cancer. The untreated and relapsed or refractory CADENZA cohorts should be reported separately.

What research teams should watch

Rapid pathology confirmation and referral matter when a rare diagnosis may be missed. Align disease assessment and record whether treatment is intended as a bridge to transplant.

PRIMARY RECORDS

Sources